-
Alexion to Present at Upcoming Virtual Investor Conferences
Alexion to Present at Upcoming Virtual Investor Conferences
Share
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the following upcoming investor conferences:
- Stifel 2020 Virtual Healthcare Conference, taking place on Tuesday, November 17th, 2020 from 10:00-10:30 a.m. ET.
- 3rd Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, December 1st, 2020 from 8:50-9:35 a.m. ET.
Audio webcasts of the presentations will be available live at: http://ir.alexion.com. Archived versions of the remarks will also be available through the Company’s website for a limited time following the conferences.
[ALXN-G]
Contacts
Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309
Alexion Pharmaceuticals
More News From Alexion Pharmaceuticals
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)
BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
